57c4a274-647d-4499-a8f8-a79e446ab4a7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.540
- ALLOGRAFT_REJECTION+0.510
- E2F_TARGETS+0.510
- INTERFERON_GAMMA_RESPONSE+0.490
- G2M_CHECKPOINT+0.450
- COMPLEMENT+0.350
- IL6_JAK_STAT3_SIGNALING+0.350
- INFLAMMATORY_RESPONSE+0.350
- MITOTIC_SPINDLE+0.310
- IL2_STAT5_SIGNALING+0.250
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.290
- WNT_BETA_CATENIN_SIGNALING-0.270
- ANDROGEN_RESPONSE-0.230
- PROTEIN_SECRETION-0.210
- PEROXISOME-0.200
- NOTCH_SIGNALING-0.160
- UNFOLDED_PROTEIN_RESPONSE-0.140
- BILE_ACID_METABOLISM-0.130
- PI3K_AKT_MTOR_SIGNALING-0.120
- MYC_TARGETS_V1-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2304 | Med | Medulloblastoma | 0.804 |
| 2 | 4ff81b7f-2dbc-453f-a68b-fe40315b2ef7 | — | — | 0.797 |
| 3 | 346fe4c0-2ea0-45b4-8863-b0f9e7756ad6 | — | — | 0.794 |
| 4 | s0099965 | — | — | 0.787 |
| 5 | MNG539 | — | — | 0.782 |
| 6 | C3L-02954 | — | cohortA1 | 0.781 |
| 7 | MNG745 | — | — | 0.775 |
| 8 | R50 | — | — | 0.773 |
| 9 | MDT-AP-1196 | Med | Medulloblastoma | 0.771 |
| 10 | TCGA-21-1070-01A-01R-0692-07 | — | cohortSQ1 | 0.771 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.140 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |